Clinical Trials Directory

Trials / Completed

CompletedNCT01641133

Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™

Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
457 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
6 Weeks – 12 Weeks
Healthy volunteers
Accepted

Summary

The primary aim of this study is to assess the reactogenicity of Synflorix vaccine and Prevenar 13 vaccine after primary vaccination at 2 and 4 months of age with either Synflorix or Prevenar 13 vaccine or Prevenar 13 and Synflorix, respectively. In addition, this study aims at assessing the safety, reactogenicity, immunogenicity and antibody persistence (approximately 8-11 months following primary vaccination) of the Synflorix vaccine and Prevenar 13 vaccine after primary vaccination at 2 and 4 months of age with either Synflorix or Prevenar 13 vaccine or Prevenar 13 and Synflorix, respectively. This study also aims at assessing the safety, reactogenicity and immunogenicity of the Synflorix vaccine when given as a booster dose at 12-15 months of age following primary vaccination at 2 and 4 months of age with either Synflorix vaccine or Prevenar 13 vaccine or Prevenar 13 and Synflorix respectively.

Detailed description

This study is partially blinded as the primary phase will be conducted in an observer-blind method and booster phase will be open method.

Conditions

Interventions

TypeNameDescription
BIOLOGICALSynflorix (3-Dose)3 doses administered intramuscularly
BIOLOGICALSynflorix (2-Dose)2 doses administered intramuscularly
BIOLOGICALSynflorix (Single Dose)1 dose administered intramuscularly
BIOLOGICALPrevenar 13 (Single Dose)1 dose administered intramuscularly
BIOLOGICALPrevenar 13 (2-Dose)2 doses administered intramuscularly

Timeline

Start date
2012-09-04
Primary completion
2013-07-15
Completion
2014-05-07
First posted
2012-07-16
Last updated
2021-03-02
Results posted
2017-02-27

Locations

3 sites across 1 country: Mexico

Source: ClinicalTrials.gov record NCT01641133. Inclusion in this directory is not an endorsement.